Evaluation of the Early Results of Percutaneous Ethanol Ablation in Patients with Primary Hyperparathyroidism

Yankova I.; Shinkov A.; Kovatcheva R.

doi:10.2478/amb-2022-0001

Acta Medica Bulgarica (Apr 2022)

Evaluation of the Early Results of Percutaneous Ethanol Ablation in Patients with Primary Hyperparathyroidism

Yankova I.,
Shinkov A.,
Kovatcheva R.

Affiliations

Yankova I.: Department of Thyroid and Metabolic Bone Diseases, University Hospital of Endocrinology “Acad. Ivan Penchev”, Department of Endocrinology, Medical University – Sofia, Bulgaria
Shinkov A.: Department of Thyroid and Metabolic Bone Diseases, University Hospital of Endocrinology “Acad. Ivan Penchev”, Department of Endocrinology, Medical University – Sofia, Bulgaria
Kovatcheva R.: Department of Thyroid and Metabolic Bone Diseases, University Hospital of Endocrinology “Acad. Ivan Penchev”, Department of Endocrinology, Medical University – Sofia, Bulgaria

DOI: https://doi.org/10.2478/amb-2022-0001
Journal volume & issue: Vol. 49, no. 1
pp. 5 – 11

Abstract

Read online

Percutaneous ethanol ablation (PEA) is an alternative non-surgical method for the treatment of patients with primary hyperparathyroidism (PHPT), suitable in cases with comorbidities and high surgical risk.

Published in Acta Medica Bulgarica

ISSN: 0324-1750 (Print); 2719-5384 (Online)
Publisher: Sciendo
Country of publisher: Poland
LCC subjects: Medicine
Website: https://sciendo.com/journal/AMB

About the journal

Abstract

Keywords